Preliminary clinical data on a new photodynamic therapy photosensitizer: 2-1-hexyloxyethyl-2-devinylpyropheophorbide-a (HPPH) for treatment of obstructive esophageal cancer

摘要

Abstract: The hexyl ether derivative or HPPH, has been identified as an optimal active in vivo photosensitizer in pre-clinical studies and has been evaluated clinically in obstructive esophageal cancer in five patients to date. The photosensitizer appears to have no systemic toxicity and be effective at low drug and light doses. Further, cutaneous photosensitivity appears to persist only 5-7 days. !3